‘Envlo’ of Daewoong Pharmaceutical, to be launched in the global markets... Entering the 1.54 billio..
.jpg)
Daewoong Pharmaceutical Reaches Sales of KRW 1.16 Trillion in 2022, Fexuclue Leads The Highest Reven..
Daewoong Pharmaceutical begins the first administration of the Bersiporocin, new treatment for idiop..
Daewoong enters exclusive licensing agreement with CS Pharmaceuticals for Bersiporocin in Idiopathic..
.jpg)
“Expected to change GERD drug market landscape” Daewoong Pharmaceutical submitted NDA for its global..
.jpg)
Daewoong Pharmaceutical announces success in developing a new antidiabetic medication and its aims t..
Daewoong Pharmaceutical Surpasses KRW 300 Billion in Q3 Revenue… Nabota Sales Grew by 93%, Leading O..
Daewoong Pharmaceutical Presents Phase 3 Clinical Trial Results of New Diabetes Treatment ‘Enavoglif..
.jpg)
Daewoong Pharmaceutical Announces US FDA Clearance of IND Application for DWP213388, First-in-class ..
.jpg)
Daewoong Pharmaceutical begins multinational phase 2 clinical trial for DWN12088, a new drug for idi..
.jpg)
Daewoong Pharmaceutical announced first-quarter 2022 results
Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue Tablets to the Philippines
